Biotechnology
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

$384.6M

Market Cap • 11/18/2024

2015

(9 years)
Founded

2020

(4 years ago)
IPO

NASDAQ

Listing Exchange
Flag of US

Emeryville

Headquarters • California